Press releases

19
May 2014
20:30 E.S.T.

TAL-effector nuclease: The USPTO issues a fourth patent licensed to Cellectis

Read more
11
Apr 2014
20:30 E.S.T.

Cellectis: 2013 financial results

Read more
31
Mar 2014
20:30 E.S.T.

Cellectis announces the closing of €20.5 M share capital increase subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors

Read more
31
Mar 2014
20:30 E.S.T.

Cellectis Receives €20.5 M in Commitments in Private Placement from U.S. Biotechnology Specialist Institutional Investors

Read more
17
Feb 2014
21:30 E.S.T.

Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors

Read more
5
Feb 2014
21:30 E.S.T.

US Patent Institutions recognize the patentability of Institut Pasteur/Cellectis early inventions on Meganucleases

Read more
4
Feb 2014
21:30 E.S.T.

Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models

Read more
30
Jan 2014
21:30 E.S.T.

Cellectis plant sciences and Bayer CropScience extend their partnership to improve crops by gene editing

Read more
30
Jan 2014
21:30 E.S.T.

Precision BioSciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology

Read more
17
Jan 2014
21:30 E.S.T.

Axxam and Cellectis bioresearch announce their collaboration to offer a new generation of cell based assays

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US